Stempoint Capital LP Takes Position in Alkermes plc $ALKS

Stempoint Capital LP acquired a new position in Alkermes plc (NASDAQ:ALKS) in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 80,492 shares of the company’s stock, valued at approximately $2,846,000.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Sanctuary Advisors LLC raised its stake in Alkermes by 2.7% in the fourth quarter. Sanctuary Advisors LLC now owns 12,141 shares of the company’s stock valued at $340,000 after buying an additional 315 shares during the last quarter. PNC Financial Services Group Inc. grew its stake in shares of Alkermes by 3.5% during the fourth quarter. PNC Financial Services Group Inc. now owns 10,326 shares of the company’s stock worth $289,000 after acquiring an additional 351 shares during the last quarter. Orion Porfolio Solutions LLC grew its stake in shares of Alkermes by 4.5% during the third quarter. Orion Porfolio Solutions LLC now owns 8,762 shares of the company’s stock worth $263,000 after acquiring an additional 376 shares during the last quarter. Horizon Investments LLC increased its holdings in shares of Alkermes by 0.9% during the third quarter. Horizon Investments LLC now owns 43,002 shares of the company’s stock valued at $1,290,000 after acquiring an additional 387 shares in the last quarter. Finally, Tidal Investments LLC raised its position in shares of Alkermes by 1.1% in the 2nd quarter. Tidal Investments LLC now owns 35,130 shares of the company’s stock valued at $1,005,000 after purchasing an additional 395 shares during the last quarter. 95.21% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Alkermes news, EVP Craig C. Hopkinson sold 9,000 shares of Alkermes stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $51.51, for a total transaction of $463,590.00. Following the completion of the sale, the executive vice president directly owned 73,389 shares in the company, valued at approximately $3,780,267.39. The trade was a 10.92% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP David Joseph Gaffin sold 2,034 shares of Alkermes stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $43.05, for a total transaction of $87,563.70. Following the sale, the executive vice president owned 229,524 shares of the company’s stock, valued at approximately $9,881,008.20. The trade was a 0.88% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 35,102 shares of company stock valued at $1,494,410. 4.59% of the stock is owned by insiders.

Alkermes Trading Down 4.3%

Alkermes stock opened at $48.34 on Thursday. The stock has a 50-day moving average price of $47.73 and a 200 day moving average price of $37.95. The company has a market capitalization of $8.06 billion, a price-to-earnings ratio of 127.21 and a beta of 0.34. Alkermes plc has a 52 week low of $25.17 and a 52 week high of $55.67. The company has a quick ratio of 1.70, a current ratio of 2.35 and a debt-to-equity ratio of 0.82.

Analyst Ratings Changes

ALKS has been the subject of a number of recent analyst reports. Piper Sandler reiterated an “overweight” rating and issued a $65.00 target price (up from $43.00) on shares of Alkermes in a research note on Tuesday. TD Cowen raised their price target on shares of Alkermes from $42.00 to $50.00 and gave the stock a “buy” rating in a report on Monday, June 22nd. Weiss Ratings downgraded shares of Alkermes from a “hold (c+)” rating to a “hold (c)” rating in a research note on Monday, May 11th. Stifel Nicolaus reissued a “buy” rating and set a $63.00 price objective (up from $45.00) on shares of Alkermes in a report on Monday, July 20th. Finally, Zacks Research raised Alkermes from a “strong sell” rating to a “hold” rating in a research report on Monday, April 27th. One analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Alkermes presently has an average rating of “Moderate Buy” and a consensus target price of $54.56.

Alkermes News Roundup

Here are the key news stories impacting Alkermes this week:

• Positive Sentiment: Alkermes reported second-quarter revenue of approximately $496 million, up 27.2% year over year and well above the roughly $457 million analyst consensus. Adjusted earnings also exceeded expectations, supported by higher sales of VIVITROL, ARISTADA, LYBALVI and the growing LUMRYZ product. Alkermes Q2 2026 earnings report
• Positive Sentiment: Adjusted EBITDA increased to $139.2 million from $126.5 million a year earlier, while the company maintained its full-year 2026 revenue outlook of $1.73 billion to $1.84 billion. Alkermes Q2 revenue and outlook
• Positive Sentiment: Robert W. Baird raised its price target from $48 to $58 and upgraded its rating to “outperform,” signaling confidence in Alkermes’ commercial growth and pipeline. Baird price target update
• Positive Sentiment: Investors have upcoming pipeline catalysts, including initial ADHD data for ALKS 7290 and year-end results from the alixorexton Phase 2 study in idiopathic hypersomnia.
• Neutral Sentiment: JPMorgan raised its price target from $60 to $61 but retained a “neutral” rating, implying upside potential while maintaining a cautious view of the shares. JPMorgan price target update
• Negative Sentiment: Third-quarter revenue guidance of $450 million to $470 million is below the approximately $472 million consensus estimate, creating concern about slower near-term growth.
• Negative Sentiment: GAAP net income fell to about $0.5 million from $87.1 million a year earlier, and Alkermes widened its expected 2026 GAAP net loss to $95 million-$115 million. The company is also preparing for CEO Blair Jackson to replace Richard Pops on August 1, adding a transition-related overhang. Alkermes Q3 guidance and CEO transition

About Alkermes

Alkermes plc is a biopharmaceutical company focused on developing innovative medicines to address unmet needs in the central nervous system (CNS). The company applies its proprietary drug delivery technologies and therapeutic expertise to advance treatments for addiction, schizophrenia, bipolar I disorder and depression. Alkermes’ portfolio includes both commercial products and a pipeline of investigational therapies designed to improve patient outcomes and support long-term disease management.

Alkermes’ commercial franchise features several approved products.